During her studies, Elisabeth Fuchs investigated albumin-based drug designs for immunotherapy. Albumin has emerged as a promising non-immunogenic drug delivery platform with long circulatory half-life and natural accumulation at disease site, that can potentially overcome limitations, such as systemic toxicity, associated with some immunotherapeutics. This work explores two different strategies to exploit albumin for immunotherapy, preformulation with recombinant albumin and binding to endogenous albumin pool, designed for the treatment of cancer and inflammatory disease.

The PhD degree was completed at the Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University.

This summary was prepared by the PhD student.

Time: Thursday 4 December 2025 at 13.00
Place: Building 1531 Room 219 (Auditorium D), Ny Munkegade 116, 8000 Aarhus C
Title of dissertation: Albumin-Based Drug Designs for Immunotherapy
Contact information: Elisabeth Fuchs, e-mail: efuchs@inano.au.dk
Members of the assessment committee:
Professor Twan Lammers, Institute for Experimental Molecular Imaging, RWTH Aachen University, Germany
Professor Henrik Vorum, Klinisk Institut, Aalborg University Hospital, Denmark
Professor Duncan Sutherland (chair), Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark
Main supervisor: Associate Professor Kenneth A. Howard
Language: The PhD dissertation will be defended in English

The defense is public.
The PhD thesis is available for reading at the Graduate School of Natural Sciences/GSNS, Ny Munkegade 120, building 1521, 8000 Aarhus C.